Live corpus
Active intelligence prompt Pediatric cancer: surface high-value therapeutic signals across pediatric oncology literature.
PEDIATRIC CANCER RESEARCH INTELLIGENCE

Finding therapies hidden in 40,244 pediatric cancer papers.

Neurocompute scores pediatric oncology literature, surfaces overlooked therapeutic signals, and turns fragmented childhood cancer research into a living discovery terminal.

40,244 Papers indexed
1,440 Papers AI scored
40,244 Ranked papers
100.0% Coverage
PATIENT-FRIENDLY SUMMARY

CHIP-AML22: a complex clinical trial in de novo pediatric AML patients, including a gemtuzumab ozogamicin randomization and targeted therapy with quizartinib in eligible subgroups, within the NOPHO-DB-SHIP consortium.

For education only—not personal medical advice.

LIVE PEDIATRIC ONCOLOGY INTELLIGENCE
↑ Therapeutic signals emerging ↑ New pediatric cancer papers ingested ↑ Cross-paper convergence detected ↑ Human relevance scores updating ↑ Overlooked treatment paths surfacing
TOP PEDIATRIC CANCER SIGNALS

Ranked Discovery Journal Articles

View all discoveries →
LATEST PEDIATRIC CANCER PAPERS

Database feed

Last ingest 2026-11-08 10:15 AM
PEDIATRIC CANCER RESEARCH TERMINAL

All ranked pediatric cancer papers

40244 results
D
AI -
Standard 54.3
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 54.3/100. Study design: 30.0; human relevance: 80.0; therapeutic relevance: 44.0; sample size: 20.0; recency: 100.0; abstract quality: 85.0.

D
AI -
Standard 54.3
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 54.3/100. Study design: 50.0; human relevance: 55.0; therapeutic relevance: 39.0; sample size: 20.0; recency: 100.0; abstract quality: 85.0.

D
Spinal Myeloid Sarcoma Revealing Acute Myeloid Leukemia in a Child: A Case Report.
PMID 42626446 Published: 2026-07-21 Ingested: 2026-08-23 09:15 AM Cureus
AI -
Standard 54.3
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 54.3/100. Study design: 30.0; human relevance: 80.0; therapeutic relevance: 44.0; sample size: 20.0; recency: 100.0; abstract quality: 85.0.

D
Pediatric extranasal, EBV-negative, extranodal natural killer/T-cell lymphoma; case report.
PMID 42422533 Published: 2026-06-24 Ingested: 2026-08-02 12:06 AM Pathology oncology research : POR
AI -
Standard 54.3
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 54.3/100. Study design: 30.0; human relevance: 80.0; therapeutic relevance: 44.0; sample size: 20.0; recency: 100.0; abstract quality: 85.0.

D
Molecular changes during AT/RT progression associated with epithelial-mesenchymal transition and extracellular matrix changes.
PMID 42384079 Published: 2026-07-01 Ingested: 2026-08-02 12:07 AM Acta neuropathologica
AI -
Standard 54.3
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 54.3/100. Study design: 50.0; human relevance: 55.0; therapeutic relevance: 39.0; sample size: 20.0; recency: 100.0; abstract quality: 85.0.

D
Hierarchical lineage tracing reveals diverse pathways of cytarabine resistance.
PMID 42380134 Published: 2026-06-30 Ingested: 2026-08-02 12:07 AM Nature communications
AI -
Standard 54.3
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 54.3/100. Study design: 50.0; human relevance: 55.0; therapeutic relevance: 39.0; sample size: 20.0; recency: 100.0; abstract quality: 85.0.

D
Case Report: Clinical case of a giant plexiform neurofibroma of the liver in a patient with deletion of exon 1 of the NF1 gene.
PMID 42326323 Published: 2026-06-04 Ingested: 2026-08-02 12:06 AM Frontiers in oncology
AI -
Standard 54.3
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 54.3/100. Study design: 30.0; human relevance: 80.0; therapeutic relevance: 44.0; sample size: 20.0; recency: 100.0; abstract quality: 85.0.

D
AI -
Standard 54.3
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 54.3/100. Study design: 30.0; human relevance: 80.0; therapeutic relevance: 44.0; sample size: 20.0; recency: 100.0; abstract quality: 85.0.

Previous
Page 2688 of 3354
Next
Before you continue

AI-assisted research information

Neurocompute uses AI to summarize scientific papers, interpret research signals, and suggest relevant reference links. AI-generated content can be incomplete, misleading, or wrong, and generated links may be irrelevant or unavailable.

Our reviewed outputs have performed strongly to date, but past accuracy is not a guarantee. Verify summaries, scores, claims, and links against the original publication before relying on them.

This platform is for research and education only. It does not provide medical advice, diagnosis, treatment recommendations, or clinical guidance.

Pediatric cancer research intelligence graphic
PEDIATRIC CANCER VISUAL SYSTEM

Open the Research Intelligence Map

Explore the active pediatric oncology analysis view.

Expand Intelligence View →
Full Pediatric cancer research intelligence graphic